Lumpy export order pattern
Oncology exports are tender-driven and may not follow a smooth quarterly trajectory, making near-term revenue lumpy.
medium · management_commentarySakar Healthcare Limited — Q4 FY26
Sakar Healthcare delivered a strong Q4 FY26 with revenue of ₹71.1 crore (+42% YoY), EBITDA of ₹26.2 crore (37% margin), and PAT of ₹11.0 crore (+91% YoY).
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Regulatory approval delays for Accord products
Only 2 of 9 Accord tech transfers are commercialized; remaining 7 await EMA approval, which could slip.
high · analyst_questionGeopolitical and freight cost risks
Middle East conflict could indirectly impact API costs and logistics, though management claims contractual pass-through.
low · analyst_question